X

Drug Profile

AB 31

Alternative Names: AB-31

Latest Information Update: 05 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AUTOTAC Bio
Class Antineoplastics
Mechanism of Action Apoptosis stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Lung cancer

Most Recent Events

02 Aug 2024 Early research in Lung cancer in South Korea (unspecified route)
02 Aug 2024 AUTOTAC Bio plans a preclinical studies for Lung cancer in between 2025 to 2026 (Unspecified route) (AUTOTAC Bio pipeline, August 2024)
14 May 2024 AUTOTAC Bio has patent protection for novel P62 ligand compound and composition in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com